Synergistic Effects of Peptides and Traditional Supplements
No study has tested MOTS-c or SS-31 together with creatine, CoQ10 or NAD+ precursors in people, so synergy is still a hypothesis. This page rates each supplement's own evidence and the stacks users report.
Understanding Synergy
What is Synergy?
Two compounds are synergistic when the combined effect is greater than the individual effects added together. As of October 2026, no published study has tested MOTS-c or SS-31 with any supplement in people. The closest is a 2026 mouse stroke study where SS-31 plus NMN protected the brain better than either alone. So the synergy in stack guides is a hypothesis built from mechanisms.
Why Combine Approaches?
- Target different steps of mitochondrial function
- Provide substrates or cofactors the peptides' targets use
Key Supplement Categories
Mitochondrial Cofactors
- CoQ10: Electron transport. A 2025 meta-analysis of 24 trials found it raises blood CoQ10, but performance effects were small and inconsistent.
- Alpha-lipoic acid: Antioxidant, metabolism. Human trials are mostly in diabetic nerve pain.
- PQQ: Mitochondrial biogenesis. In 23 untrained men it raised a biogenesis marker (PGC-1α) but not aerobic performance.
- B vitamins: Enzyme cofactors
NAD+ Support
NAD+ is critical for mitochondrial function. Precursor trials are small, with modest results:
- NMN: Improved muscle insulin sensitivity in 25 women with prediabetes
- NR (Nicotinamide riboside): Raised muscle NAD+ metabolites in 12 older men without changing mitochondrial function
- Niacin: NAD+ pathway support
Energy Substrates
- Creatine: ATP regeneration. Strongest human evidence here: a 2017 meta-analysis of 22 trials in older adults found about 1.4 kg more lean mass and greater strength when creatine was added to resistance training.
- D-Ribose: ATP synthesis
- L-Carnitine: Fat transport into mitochondria. A 2021 meta-analysis found higher blood carnitine, but no change in lactate.
Synergy with MOTS-c
As of October 2026, MOTS-c has rodent data only; its analog CB4211 was discontinued. See our MOTS-c overview.
MOTS-c + NAD+ Precursors
| Component | Proposed mechanism | Evidence |
|---|---|---|
| MOTS-c | AMPK activation | Mice only |
| NMN/NR | NAD+ production | Small human trials |
| Combined | More metabolic flux | Not tested |
MOTS-c + Creatine
- MOTS-c is proposed to change energy utilization
- Creatine provides rapid ATP regeneration
- Different time scales; the combination is untested
MOTS-c + CoQ10
- Guides claim MOTS-c drives mitochondrial biogenesis
- CoQ10 could support the new mitochondria, but neither step is shown in people
Synergy with SS-31
As of October 2026, SS-31 (elamipretide) is a prescription medicine, Forzinity, with FDA accelerated approval on September 19, 2025, for Barth syndrome. Research-use vials aren't that product. In MMPOWER-3, 218 adults with mitochondrial myopathy got 40 mg/day or placebo for 24 weeks, and SS-31 missed its walking and fatigue endpoints.
SS-31 + Alpha-Lipoic Acid
| Component | Proposed mechanism | Evidence |
|---|---|---|
| SS-31 | Mitochondrial membrane protection | Approved for Barth; other trials missed |
| ALA | Regenerates other antioxidants | Mostly diabetic neuropathy |
| Combined | Broader antioxidant defense | Not tested |
SS-31 + PQQ
- SS-31 is proposed to protect existing mitochondria
- PQQ may promote mitochondrial biogenesis
- The pairing is untested
SS-31 + L-Carnitine
- SS-31 is studied for electron transport
- L-Carnitine shuttles fats for oxidation
- Untested together
Stack Protocols Users Report
These come from stack guides and forums, not tested protocols. Supplement doses are from the trials cited.
| Component | Dose | Source |
|---|---|---|
| MOTS-c | About 5 mg 2-3x weekly (10-15 mg/week) | Users |
| SS-31 | About 0.5-4 mg/day | Users (Forzinity label: 40 mg SC daily) |
| Creatine | 3-5 g/day | ISSN |
| NMN | 250 mg/day | Prediabetes trial |
| NR | 1 g/day | Older-men trial |
| Alpha-lipoic acid | 600 mg/day | Neuropathy trials |
| PQQ | 20 mg/day | Untrained-men trial |
| L-Carnitine | 1-2 g/day | 2021 meta-analysis |
For on/off schedules, see how users cycle MOTS-c and SS-31.
Timing Considerations
Daily Supplement Timing
| Supplement | Common time | Reason |
|---|---|---|
| CoQ10 | With fats | Fat-soluble absorption |
| Creatine | Any time | Consistent dosing |
Peptide + Supplement Timing
Users report SS-31 in the morning and MOTS-c before workouts; no study has tested timing.
Evidence for Combinations
Research Support
| Combination | Evidence Level | Notes |
|---|---|---|
| Peptides + CoQ10 | Untested | Mechanisms only |
| Peptides + NAD+ | Untested in people | One mouse study |
| Peptides + Creatine | Untested | Different systems |
| Exercise | Strong | Best overall evidence |
What We Know
- Creatine is well-studied; CoQ10 and NAD+ precursors are mixed
- Combinations are not studied in people
Cost-Benefit Considerations
Prioritization
Ranked by human evidence and cost:
- Exercise (free, most evidence)
- Creatine (cheap, strong evidence for strength and lean mass)
- CoQ10 (moderate cost, modest evidence)
- NAD+ precursors (moderate-high cost)
- Peptides (highest cost, no data in healthy people)
Value Assessment
| Supplement | Cost | Evidence |
|---|---|---|
| Creatine | Low | Strong |
| CoQ10 | Moderate | Modest |
| NMN | High | Limited |
| MOTS-c | Very High | Rodent only |
| SS-31 | Very High | Rx for Barth only |
Safety Considerations
Supplement Interactions
- CoQ10 may interact with warfarin and insulin (NIH)
- Injection-site reactions are the most common Forzinity side effect, and users report them with MOTS-c
- MOTS-c has no human safety data
Combined Use Monitoring
Users often describe adding one component at a time. WADA's 2026 list bans MOTS-c at all times (S4.4.1, non-Specified), while SS-31's status since approval is unverified; see MOTS-c and SS-31 in tested sport.
What We Still Don't Know
Nobody has tested whether a peptide plus a supplement beats the supplement alone in people. MOTS-c still lacks a first human study, and SS-31 hasn't been studied in healthy lifters.
Stay Updated on Peptide Research
Get weekly breakdowns of new studies, dosing insights, and community protocols. No spam, unsubscribe anytime.
References
- ISSN position stand: safety and efficacy of creatine supplementation (Journal of the International Society of Sports Nutrition, 2017)
- Creatine during resistance training in older adults: meta-analysis of lean mass and strength (Open Access Journal of Sports Medicine, 2017)
- CoQ10 raises blood levels but shows limited, inconsistent performance effects: meta-analysis (British Journal of Nutrition, 2025)
- CoQ10 and exercise-induced muscle damage: dose-response meta-analysis of 28 RCTs (Clinical Nutrition ESPEN, 2024)
- NMN increases muscle insulin sensitivity in prediabetic women (Science, 2021)
- Nicotinamide riboside and the aged human skeletal muscle NAD+ metabolome (Cell Reports, 2019)
- PQQ supplementation, aerobic performance and mitochondrial biogenesis in untrained men (Journal of the American College of Nutrition, 2020)
- L-carnitine and physical performance in healthy subjects: systematic review and meta-analysis (Journal of Functional Morphology and Kinesiology, 2021)
- Alpha-lipoic acid and gamma-linolenic acid in diabetic peripheral neuropathy: network meta-analysis (Canadian Journal of Diabetes, 2024)
- SS-31 and NMN combination in a mouse model of ischemic stroke (Neurochemical Research, 2026)
- MMPOWER-3 randomized trial of elamipretide in primary mitochondrial myopathy (Neurology, 2023)
- FDA grants accelerated approval to first treatment for Barth syndrome (FDA, 2025)
- Forzinity (elamipretide) prescribing information (FDA, 2025)
- WADA 2026 Prohibited List (WADA, 2025)
- Coenzyme Q10: usefulness and safety (NCCIH, accessed October 2026)